Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Nov
05
Today In Oncology
Basser Center for BRCA Awards 2026 Global Prize
Triplet Therapy With Abiraterone Improves OS Long-Term in Metastatic Castration-Sensitive Prostate Cancer
Phase III VOLGA Trial Explores Outcomes in Muscle Invasive Bladder Cancer
First-Line Pembrolizumab Improves Progression-Free Survival in dMMR Advanced Endometrial Cancer
Bispecific ADC May Offer New Treatment Option for HR-Positive, HER2-Negative Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo